These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 30603246)

  • 1. Baseline low-density lipoprotein cholesterol predicts the hemoglobin A1c-lowering effect of dapagliflozin in Japanese patients with type 2 diabetes mellitus.
    Iwasaki T; Yoneda M
    Diabetol Int; 2016 Mar; 7(1):77-82. PubMed ID: 30603246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: a single-center, open-label, single-arm, pilot study.
    Iwasaki T; Kessoku T; Higurashi T; Taguri M; Yoneda M
    Diabetol Int; 2018 Jul; 9(3):189-195. PubMed ID: 30603366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
    Hayashi T; Fukui T; Nakanishi N; Yamamoto S; Tomoyasu M; Osamura A; Ohara M; Yamamoto T; Ito Y; Hirano T
    Cardiovasc Diabetol; 2017 Jan; 16(1):8. PubMed ID: 28086872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis.
    Brown RE; Gupta N; Aronson R
    Diabetes Technol Ther; 2017 Nov; 19(11):685-691. PubMed ID: 28829163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study.
    Tobita H; Sato S; Miyake T; Ishihara S; Kinoshita Y
    Curr Ther Res Clin Exp; 2017; 87():13-19. PubMed ID: 28912902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus.
    Elkind-Hirsch KE; Seidemann E; Harris R
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100139. PubMed ID: 33345876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes With Established Ischemic Heart Disease (EDIFIED).
    Zainordin NA; Hatta SFWM; Mohamed Shah FZ; Rahman TA; Ismail N; Ismail Z; Abdul Ghani R
    J Endocr Soc; 2020 Jan; 4(1):bvz017. PubMed ID: 31993550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medium- and Long-Term Effects of Dapagliflozin on Serum Uric Acid Level in Patients with Type 2 Diabetes: A Real-World Study.
    Wang S; Yuan T; Song S; Duo Y; Zhao T; Gao J; Fu Y; Dong Y; Zhao W
    J Pers Med; 2022 Dec; 13(1):. PubMed ID: 36675682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial.
    Ito D; Inoue K; Saito D; Hamaguchi K; Kaneko K; Sumita T; Inukai K; Inoue I; Shimada A
    Diabetes Ther; 2021 Dec; 12(12):3201-3215. PubMed ID: 34709582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus.
    Hayakawa T; Kato KI; Kobuchi S; Kataoka K; Sakaeda T
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study).
    Nakajima H; Okada S; Mohri T; Kanda E; Inaba N; Hirasawa Y; Seino H; Kuroda H; Hiyoshi T; Niiya T; Ishii H
    Diabetol Metab Syndr; 2018; 10():11. PubMed ID: 29507611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well-controlled plasma LDL cholesterol.
    Bouter KEC; van Bommel EJM; Jansen H; van Harskamp D; Schierbeek H; Ackermans MT; Serlie MJ; Schimmel AWM; Nieuwdorp M; Dallinga-Thie GM; van Raalte DH
    Diabetes Obes Metab; 2020 Jun; 22(6):988-996. PubMed ID: 32026592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan.
    Chen JF; Peng YS; Chen CS; Tseng CH; Chen PC; Lee TI; Lu YC; Yang YS; Lin CL; Hung YJ; Chen ST; Lu CH; Yang CY; Chen CC; Lee CC; Hsiao PJ; Jiang JY; Tu ST
    PeerJ; 2020; 8():e9998. PubMed ID: 33240585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
    Tang Y; Sun Q; Bai XY; Zhou YF; Zhou QL; Zhang M
    Nutr Diabetes; 2019 Nov; 9(1):32. PubMed ID: 31685792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.
    Han E; Kim A; Lee SJ; Kim JY; Kim JH; Lee WJ; Lee BW
    Diabetes Ther; 2018 Aug; 9(4):1689-1701. PubMed ID: 29998370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study.
    Scheerer MF; Rist R; Proske O; Meng A; Kostev K
    Diabetes Metab Syndr Obes; 2016; 9():337-345. PubMed ID: 27822077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of replacing metformin with pioglitazone on glycemic control in japanese patients with poorly controlled type 2 diabetes mellitus: A 12-week, open-label, prospective study.
    Sakaue S; Kamigaki M; Yoshimura H; Nishimura M
    Curr Ther Res Clin Exp; 2008 Aug; 69(4):364-77. PubMed ID: 24692813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.